359 199 6.1 ± 3.5 26.4 ± 5.7 8.1 ± 2.7 3.1 ± 1.3 2.3 ± 1.5 60.1 ± 6.9 15.2 ± 8.4 14.2 ± 4.8 RvD6 359 159 3.4 ± 2.2 4.8 ± 1.2 1.8 ± 0.5 0.4 ± 0.1 2.7 ± 0.2 5.9 ± 2.2 0.5 ± 0.2 2.4 ± 0.8 4,14-diHDHA 359 101 3.6 ± 0.9 10.5 ± 1.9 12.3 ± 2.4 4.1 ± 1.3 4.4 ± 1.5 30.1 ± 3.2 8.0 ± 2.9 26.7 ± 18.4 MaR1 359 221 7.0 ± 4.8 7.2 ± 2.1 1.1 ± 0.8 0.4 ± 0.4 3.6 ± 1.4 9.0 ± 2.9 0.7 ± 0.5 4.0 ± 2.3 20-OH-MaR1 375 221 5.2 ± 2.7
9.5 ± 6.5 6.5 ± 2.3 2.3 ± 0.9 1.8 ± 1.2 37.6 ± 2.5 10.6 ± 5.8 9.3 ± 3.8 PD1 359 153 8.9 ± 3.6 38.7 ± 8.2 5.0 ± 0.9 2.8 ± 0.5 10.3 ± 2.0 90.5 ± 7.7 4.2 ± 1. 16.3 ± 4.5 18.3 ± 5.5 12.5 ± 4.0 13.9 ± 4.3 17.9 ± 2.4 11.8 ± 2.1 35.0 ± 24.4 EPA 301 283 3.6 ± 1.1 3.5 ± 2.5 1.5 ± 0.7 2.4 ± 0.9 2.3 ± 0.5 8.6 ± 0.7 1.3 ± 0.9 3.3 ± 0.7
Mice were subjected to right-sided cervical vagotomy or sham surgery and then challenged with 1 mg zymosan. Peritoneal exudates were collected at the indicated intervals and lipid mediator profi les determined by lipid mediator metabololipidomics (see Materials and methods). Individual bioactive lipid mediator and precursor/pathway markers where: Q1, M-H (parent ion); and Q3, diagnostic ion in the MS/MS (daughter ion) along with mean ± SEM values for each of the mediators identifi ed in the 4-h exudates. The detection limit was ‫ف‬ 1 pg. *, below limits. Results are representative of two separate experiments ( n = 4 mice per group). 
